

1 **Cell type-specific network analysis in Diversity Outbred mice identifies genes**  
2 **potentially responsible for human bone mineral density GWAS associations**

3  
4 Luke J Dillard<sup>1</sup>, Gina M Calabrese<sup>1</sup>, Larry D Mesner<sup>1,2</sup>, Charles R Farber<sup>1,2,3</sup>

5  
6 <sup>1</sup>Center for Public Health Genomics, School of Medicine, University of Virginia, Charlottesville,  
7 VA 22908

8 <sup>2</sup>Department of Public Health Sciences, School of Medicine, University of Virginia,  
9 Charlottesville, VA 22908

10 <sup>3</sup>Department of Biochemistry and Molecular Genetics, School of Medicine, University of  
11 Virginia, Charlottesville, VA 22908

12  
13 Correspondence to:

14  
15 Charles R. Farber  
16 E-mail: crf2s@virginia.edu  
17 Center for Public Health Genomics  
18 University of Virginia  
19 P.O. Box 800717  
20 Charlottesville, VA 22908, USA

21 Tel. 434-243-8584

22 **Summary**

23

24 Genome-wide association studies (GWASs) have identified many sources of genetic variation

25 associated with bone mineral density (BMD), a clinical predictor of fracture risk and

26 osteoporosis. Aside from the identification of causal genes, other difficult challenges to

27 informing GWAS include characterizing the roles of predicted causal genes in disease and

28 providing additional functional context, such as the cell type predictions or biological pathways

29 in which causal genes operate. Leveraging single-cell transcriptomics (scRNA-seq) can assist in

30 informing BMD GWAS by linking disease-associated variants to genes and providing a cell type

31 context for which these causal genes drive disease. Here, we use large-scale scRNA-seq data

32 from bone marrow-derived stromal cells cultured under osteogenic conditions (BMSC-OBs)

33 from Diversity Outbred (DO) mice to generate cell type-specific networks and contextualize

34 BMD GWAS-implicated genes. Using trajectories inferred from the scRNA-seq data that map

35 cell state transitions, we identify networks enriched with genes that exhibit the most dynamic

36 changes in expression across trajectories. We discover 21 network driver genes, which are likely

37 to be causal for human BMD GWAS associations that colocalize with expression/splicing

38 quantitative trait loci (eQTL/sQTL). These driver genes, including *Fgfrl1* and *Tpx2*, along with

39 their associated networks, are predicted to be novel regulators of BMD via their roles in the

40 differentiation of mesenchymal lineage cells. In this work, we showcase the use of single-cell

41 transcriptomics from mouse bone-relevant cells to inform human BMD GWAS and prioritize

42 genetic targets with potential causal roles in the development of osteoporosis.

43

44

45 **Introduction**

46

47 Osteoporosis is a complex disease characterized by low bone mineral density (BMD),

48 bone fragility, and an increased risk of fracture<sup>1</sup>. BMD, a highly heritable trait, is one of the most

49 important clinical predictors of osteoporotic fracture<sup>2,3</sup>. Increasing our understanding of the

50 genetic basis of BMD is critical for the development of approaches for the treatment and

51 prevention of osteoporosis. In recent years, genome-wide association studies (GWAS) have

52 made great progress in unraveling BMD genetics by identifying over 1,100 independent

53 associations<sup>4</sup>. Now the challenge lies in pinpointing causal genes, which is necessary for the

54 translation of genetic findings into novel therapies.

55 A number of approaches exist to identify genes responsible for GWAS associations<sup>5-8</sup>.

56 Most rely on population-based “-omics” data<sup>9</sup>, which are scarce for human bone, to connect

57 associations to causal genes. Our group has used co-expression networks generated from mouse

58 bone transcriptomic datasets to assist in the identification of genes likely responsible for BMD

59 associations. One significant advantage of this approach is its ability to utilize the network

60 connections of candidate genes to predict how these candidate genes may affect BMD. For

61 example, we generated co-expression networks from bone tissue and primary osteoblasts in

62 mouse genetic reference populations and identified multiple co-expression modules enriched

63 with genes located in BMD associations<sup>10,11</sup>. We then cross-referenced genes in these modules

64 with those regulated by co-localizing expression quantitative trait loci (eQTLs) from the Gene-

65 Tissue Expression project (GTEx)<sup>12,13</sup> to identify "high priority" genes. Recently, we expanded

66 our analyses to include directed networks generated via a Bayesian approach using cortical bone

67 RNA-seq data from 192 Diversity Outbred (DO) mice. By combining key driver analysis and

68 GTEEx eQTL colocalization data, we identified 19 novel genes, such as *SERTAD4* and *GLT8D2*,  
69 which are likely causal for human BMD GWAS associations<sup>14</sup>.

70 To date, our analyses have been reliant on networks generated from heterogeneous bulk  
71 transcriptomics (RNA-seq) datasets from mouse bone and primary bone cells. However,  
72 leveraging single-cell transcriptomics (scRNA-seq) data would offer the added benefit of  
73 resolving the transcriptomic profiles of discrete cell types. Additionally, using scRNA-seq data  
74 has the potential to provide context by predicting the specific cell types in which causal genes  
75 and their associated networks operate. In recent work, we demonstrated the utility of bone  
76 marrow-derived stromal cells cultured under osteogenic condition (BMSC-OB) for the  
77 generation of population-scale scRNA-seq data on bone relevant cell types<sup>15</sup>. The BMSC-OB  
78 model effectively enriches for mesenchymal lineage cells (e.g., mesenchymal progenitors,  
79 osteoblasts, osteocyte-like cells) that are highly relevant to the regulation of BMD.

80 In this work, our goal was to prioritize and contextualize genes implicated by BMD  
81 GWAS using an expanded large-scale (N=80) BMSC-OB scRNA-seq dataset on bone cell types.  
82 We accomplished this by first generating co-expression and Bayesian networks<sup>14</sup> for each  
83 BMSC-OB mesenchymal cell type. We subsequently prioritized networks based on their  
84 enrichment for genes exhibiting the most dynamic changes in expression across trajectories  
85 inferred from the scRNA-seq data, thus highlighting networks likely associated with the  
86 differentiation of BMSC-OBs. We then used these networks linked to osteogenic differentiation  
87 to prioritize genes with eQTL and/or splicing quantitative trait loci (sQTL) which colocalize with  
88 BMD GWAS associations<sup>7,16</sup>. In doing so, this analysis provides additional support for a role of  
89 these genes in the regulation of BMD and highlights their potential roles in differentiation of cell  
90 types essential to skeletal health.

91

92

## 93 Results

94

### 95 **BMSC-OBs derived from DO mice yield diverse cell types that are enriched for** 96 **mesenchymal lineage cells:**


97

98        We cultured BMSCs from a total of 80 Diversity Outbred (DO) mice, a genetically  
99 diverse outbred mouse population<sup>17,18</sup> (N=75 from the current study and N=5 from<sup>15</sup>; N□=□49  
100 male and N□=□31 females). We cultured BMSCs under osteogenic conditions and subsequently  
101 performed scRNA-seq, as described in<sup>15</sup>. After stringent processing and quality control  
102 (Materials and Methods), the dataset consisted of 21,831 expressed genes across 139,392 cells.  
103 We manually annotated 15 clusters ranging in size from 270 to 27,291 cells and identified cell  
104 types of the mesenchymal lineage as well as various other cell types (**Figure 1A**,  
105 **Supplementary File 1a, Figure 1-figure supplement 1**).

106        Based on our prior BMSC-OB scRNA-seq study<sup>15</sup>, we expected to identify a large  
107 proportion of mesenchymal cells and a smaller fraction of non-mesenchymal cell types.  
108 Consistent with this hypothesis, clusters associated with mesenchymal lineages accounted for  
109 74.1% of all cells (**Figure 1A**). These included mesenchymal progenitor cells (MPCs), late  
110 mesenchymal progenitors (LMPs), osteoblast progenitors (OBPs), two mature osteoblast  
111 populations (OB1 and OB2), osteocyte-like cells (Ocy), and marrow adipogenic lineage  
112 progenitors (MALPs). The non-mesenchymal cell types observed included macrophages,  
113 monocytes, granulocytes, T-cells, B-cells, endothelial cells, and osteoclast-like cells (**Figure**  
114 **1A**). With regards to the mesenchymal cell types, the only differences in cell clusters relative to  
115 our previous report<sup>15</sup> were the presence of MPCs and two mature osteoblast clusters. Upon  
116 comparing the two distinct osteoblast clusters, OB1 and OB2 (**Figure 1A**), both clusters had  
117 ubiquitous expression of genes associated with mature osteoblasts (e.g., *Colla1*, *Bglap*, *Sparc*,

118 and *Ibsp*) (**Supplementary File 1a**) while many of the “canonical” osteoblast markers were  
119 more highly expressed in OB1 compared to OB2 (**Supplementary File 1b**). Interestingly, MPCs  
120 did not have transcriptomic profiles similar to other mesenchymal progenitor cells previously  
121 identified by our group or others<sup>15,19</sup>. All other mesenchymal cell types demonstrated specific  
122 expression of canonical marker genes (**Figure 1A, B**).

123 We next assessed the variability in cell type frequencies across DO mice by quantifying  
124 the proportions of each annotated mesenchymal cell type. All other clusters, which mainly  
125 consisted of immune cells of hematopoietic origin, were aggregated into one group (Hem) for  
126 each mouse. We observed high variability in the raw proportional abundances of cell types  
127 derived from each mouse (**Figure 1C, Supplementary File 1c**). For example, the proportions of  
128 osteoblasts (OB1 and OB2) varied significantly among individual DO mice (**Figure 1D**). All  
129 mice used in the current experiment had been extensively phenotyped for a wide range of bone  
130 traits (microCT, histomorphometry, biomechanical bone properties, etc.) as part of a previous  
131 genetic analysis of bone strength<sup>14</sup>. We correlated cell type frequencies with bone traits,  
132 however, none of the cell type proportions were strongly correlated with any bone trait  
133 (**Supplementary File 1d-e**).



134 **Figure 1. Analysis of single cell RNA-seq (scRNA-seq) data for BMSC-OBs derived from**  
135 **80 Diversity Outbred (DO) mice.**

136 **Mesenchymal lineage cells are enriched in BMD heritability:**

137  
138        The primary goal of this work was to prioritize and contextualize genes implicated by  
139        BMD GWAS. As a first step towards this goal, we sought to determine which cell types were the  
140        most relevant to the genetics of BMD. Using the BMD GWAS and the BMSC-OB scRNA-seq  
141        data, we performed a CELLECT<sup>20</sup> cell type prioritization analysis to identify cell clusters  
142        enriched for BMD heritability. We observed that OB1, Ocy, and MALP cell clusters were  
143        significantly enriched ( $P_{adj} < 0.05$ , red dashed line) for BMD heritability ( $P_{adj} = 0.018, 0.010,$   
144        0.006, respectively) (**Figure 1E, Supplementary File 1f**). None of the non-mesenchymal cells  
145        identified were significant ( $P_{adj} > 0.05$ ) (**Figure 1E**). As a result, all downstream efforts focused  
146        solely on using data on mesenchymal cell types to inform GWAS.

147


148 **Generating mesenchymal cell type-specific Bayesian networks to inform BMD GWAS:**

149  
150        We have previously shown that network-based approaches using bulk RNA-seq are  
151        powerful tools for the identification of putative causal genes from BMD GWAS data<sup>10,11,14</sup>. Here,  
152        our goal was to apply these same approaches using the BMSC-OB scRNA-seq data to prioritize  
153        and contextualize genes we previously identified as having a colocalizing expression quantitative  
154        trait locus (eQTL; N=512) or splicing QTL (sQTL; N=732) in a tissue from the Genotype-Tissue  
155        Expression (GTEx) project<sup>7,13,16</sup>. Genes identified in each study (or both) yielded a list of high  
156        priority target genes (N = 1,037). While GTEx does not currently contain data for bone tissue,  
157        eQTL can be shared across many tissues and may exert their effects in cell types resident to  
158        bone<sup>21</sup>. Therefore, utilizing our previous work, we hypothesized that generating cell type-specific  
159        networks would yield more biologically relevant representations of processes occurring within  
160        particular mesenchymal cell types. Additionally, by integrating GWAS, cell type-specific

161 networks, and dynamic gene expression as a function of differentiation, we anticipated we would  
162 identify points of intervention in which genetic variation impacts genes involved in the  
163 differentiation process.

164 Our network analysis begins by partitioning genes into groups based on co-expression by  
165 applying iterative weighted gene co-expression network analysis (iterativeWGCNA)<sup>22</sup> to each  
166 mesenchymal cell type (Step 1, **Figure 2**). In total, 535 modules were identified from the BMSC-  
167 OB scRNA-seq data, and the number of modules identified for each mesenchymal cell cluster  
168 ranged from 26 to 153 with an average of 76 modules per cluster (**Supplementary File 1g-h**).  
169 We sought to infer causal relationships between genes in each cell type-specific co-expression  
170 module and subsequently identify networks involved in processes relevant to BMSC-OB  
171 differentiation. To this end, we generated Bayesian networks for each co-expression module,  
172 thus enabling us to model directed interactions between co-expressed genes based on conditional  
173 independence<sup>14</sup> (Step 2, **Figure 2**).

174



175  
176 **Figure 2. Overview of the network analysis pipeline**  
177


178 **Identifying putative drivers of mesenchymal cell differentiation:**

179  
180 We hypothesized that many genes impacting BMD do so by influencing osteogenic  
181 differentiation or possibly bone marrow adipogenic differentiation of key mesenchymal cell  
182 types, as suggested by the CELLECT analysis above. Therefore, the next step of our network  
183 analysis was to identify cell type-specific Bayesian networks enriched for genes potentially  
184 driving mesenchymal differentiation (Step 3, **Figure 2**). To accomplish this, we first performed a  
185 pseudotime trajectory analysis to infer paths of differentiation in the mesenchymal lineage cells.  
186 We resolved three pseudotime trajectories (two osteogenic, one adipogenic) originating from the

187 MPC cell cluster and ending in either Ocy, OB2, or MALP cell fates (**Figure 3A**). It is important  
188 to note that given the identification of multiple skeletal stem cells<sup>23–26</sup>, we do not view these  
189 trajectories as lineages, but rather “differentiation paths” (progenitor to mature and/or terminally  
190 differentiated cells) that are likely traversed by different subsets of skeletal stem cells.

191 To identify genes likely impacting BMSC-OB differentiation, we used tradeSeq to  
192 identify genes that exhibit dynamic changes in expression along pseudotime<sup>27</sup>. Prior to  
193 performing the tradeSeq analysis, we parsed the pseudotime trajectories into regions that  
194 encompass cells associated with each cell type along their respective trajectories (**Figure 3B**).  
195 We defined multiple cell type boundaries (nine in total) using pseudotime values, which  
196 represent points along a trajectory. The tradeSeq analysis was performed for each boundary  
197 (**Supplementary File 2a**). For example, trajectories bifurcate in the LMP cell cluster (**Figure**  
198 **3A**); therefore, cells belonging to the LMP cluster can map to adipogenic and/or osteogenic  
199 trajectories depending on their placement along pseudotime. Between a cell type boundary, cells  
200 spanning a specific cluster (e.g., LMP) and mapping to a specific trajectory (e.g., osteogenic  
201 trajectory) are used as input to analyze gene expression between the start and end points of the  
202 cell type boundary (e.g., LMP\_to\_OBP). We analyzed gene expression within the established  
203 cell type boundaries for all trajectories and identified genes that exhibit the most significant  
204 differences in expression between the start and end points of the cell type boundaries. The total  
205 number of significant trajectory-specific tradeSeq genes ( $P_{adj} < 0.05$ ) ranged from 87 to 1,697  
206 across the 9 cell type boundaries (**Supplementary File 2a, 2b-d**). The expression of  
207 representative marker genes for all cell types as a function of pseudotime were consistent with  
208 boundaries defined for each cell type (**Figure 3C**).

209




210 **Figure 3. Pseudotime Trajectory Inference analysis and establishment of cell type**  
 211 **boundaries for tradeSeq analysis**

212 We sought to identify tradeSeq genes that may have an associated expression quantitative  
213 trait locus (eQTL) and hypothesized that eQTLs that perturb their expression would also impact  
214 the proportion of cells at different stages along the cell trajectories. We performed a cell type-  
215 specific eQTL analysis for each mesenchymal cell type from the 80 DO mice scRNA-seq data.  
216 We identified 563 genes (eGenes) regulated by a significant *cis*-eQTL in specific cell types of  
217 the BMSC-OB scRNA-seq data. Despite being significantly underpowered for this analysis due  
218 to our relatively smaller sample size (N = 80), we identified two cell type-specific eGenes where  
219 the genotype responsible for the *cis*-eQTL effect was also associated with cell type proportions.  
220 The first of these genes was Pyruvate Kinase, muscle (*Pkm*), which was identified as a  
221 significant global tradeSeq gene ( $P_{adj} = 8.35 \times 10^{-8}$ ; **Supplementary File 2e**) associated with the  
222 transition from LMPs to OBPs along an osteogenic trajectory (**Figure 4A**). Moreover, *Pkm*  
223 served as an eGene in the LMP cell cluster ( $LOD = 9.72$ ; **Figure 4B, Supplementary File 2f**).  
224 Mice inheriting at least one PWK allele at this locus (N = 15) demonstrated lower *Pkm*  
225 expression (**Figure 4C**) and a notable reduction in mature osteoblasts (OB1) and osteocyte-like  
226 cells (Ocy) proportions ( $P = 0.030$  and  $P = 0.026$ , respectively), while LMP proportions were  
227 unaffected (**Figure 4D, Supplementary File 2g**).

228 Similarly, S100 calcium binding protein A1 (*S100a1*) was an OBP to OB1 transition  
229 tradeSeq gene ( $P_{adj} = 0.023$ ; **Figure 4A, Supplementary File 2e**) and an eGene in the OBP cell  
230 cluster ( $LOD = 10.12$ ; **Figure 4B, Supplementary File 2f**). Mice inheriting at least one 129  
231 allele at this locus (N = 30) had higher *S100a1* expression, while the opposite was observed for  
232 mice inheriting NZO alleles (N = 14) (**Figure 4C**). Additionally, mice inheriting at least one 129  
233 allele showed a significant decrease in LMP proportion and increase in OB1 proportion ( $P =$   
234 0.008 and  $P = 0.016$ , respectively) (**Figure 4D, Supplementary File 2g**), while no significant

235 differences were observed in cell type proportions among mice inheriting NZO alleles at this  
236 locus (**Figure 4-figure supplement 1, Supplementary File 2g**).

237



238

239

240

**Figure 4. TradeSeq-identified genes associated with BMSC-OB differentiation exhibit eQTL effects.**

241 **Identification of differentiation driver genes (DDG):**

242  
243 In order to discover BMSC-OB differentiation genes potentially responsible for BMD  
244 GWAS associations, the next step of our network analysis leveraged the trajectory-specific  
245 tradeSeq genes identified for each cell type boundary (**Supplementary Table File 2b-d**) to  
246 identify differentiation driver genes (DDGs) (Step 3, **Figure 2**). We identified DDGs by  
247 extracting subnetworks (i.e., large 3-step neighborhoods; see Methods) for each gene in each cell  
248 type-specific Bayesian network and identifying those subnetworks enriched ( $P_{adj} < 0.05$ ) for  
249 trajectory-specific tradeSeq genes for the cell type boundary. The analysis identified 408  
250 significant DDGs (**Supplementary File 2h-k**). We performed a PANTHER<sup>28</sup> Gene Ontology  
251 (GO) analysis for the cell type boundaries yielding a sufficient number of DDGs and found that  
252 DDGs for the osteogenic cell type boundaries (LMP\_to\_OBP, OBP\_to\_OB1, OBP\_to\_OB2)  
253 were enriched for genes associated with the cell cycle (GO:0007049; N = 23, 18, 23; P = 1.12 x  
254  $10^{-6}$ ,  $1.29 \times 10^{-13}$ ,  $1.0 \times 10^{-14}$ , respectively) (**Supplementary File 3a-c**). The DDGs for the  
255 adipogenic cell type boundary (LMP\_to\_MALP, MALP\_to\_end) were enriched for genes  
256 associated with extracellular matrix organization (GO:0030198; N = 10; P =  $1.62 \times 10^{-7}$ ) and  
257 lipid metabolic processes (GO:0006629; N = 25; P =  $1.83 \times 10^{-11}$ ), respectively (**Supplementary**  
258 **File 3d-e**). Across all 408 DDGs, 49 (12%) were identified in one or more cell type boundaries  
259 as genes with a significant alteration (P < 0.05) of whole-body BMD when knocked-out/down in  
260 mice, as reported by the International Mouse Knockout Consortium (IMPC)<sup>29</sup> (**Supplementary**  
261 **File 2i-k**).

262 We used our previously generated list of potentially causal BMD GWAS genes  
263 (N=1,037) to subsequently prioritize the DDGs (Step 4, **Figure 2**). Of the 408 DDGs, 21 DDGs  
264 in one or more cell type boundaries were genes that have BMD GWAS associations that

265 colocalize with sQTL/eQTL (**Table 1**). The majority of these DDGs were identified in LMPs  
266 along both the osteogenic (LMP\_to\_OBP) and adipogenic (LMP\_to\_MALP) trajectories (N = 10  
267 and 6, respectively; **Supplementary File 2h, Supplementary File 3f**). The remaining DDGs  
268 were identified in OBPs along both osteoblast trajectories (OBP\_to\_OB1, OBP\_to\_OB2; N = 1  
269 and 3, respectively) and MALPs (MALP\_to\_end; N = 6). Additionally, 3 of the 21 DDGs (*Tet1*,  
270 *Tpx2*, *Tim2*) are IMPC genes that exhibit a significant alteration of BMD (**Supplementary File**  
271 **2h, Supplementary File 3f**).

272 **Table 1: Prioritized Differentiation Driver Genes (DDGs) that have BMD GWAS**  
273 **associations that colocalize with splicing/expression QTL (eQTL/sQTL) identified in a**  
274 **Genotype-Tissue Expression project (GTEx) tissue.** The tissue with the most significant  
275 colocalization (RCP and/or H4PP) is listed for each DGG (26 total, 21 distinct), as determined  
276 from Al-Barghouthi *et al.* (2022) and Abood *et al.* (2023) for eQTL and sQTL, respectively<sup>7,16</sup>.  
277 RCP = Regional Colocalization Probability (GWAS and eQTL colocalization). H4PP = H4  
278 Posterior Probability (GWAS and sQTL colocalization).

Trajectory	Cell type boundary	DDG	GTEX Tissue with strongest eQTL colocalization (RCP)	GTEX Tissue with strongest sQTL colocalization (H4PP)	eGene identified from scRNA-seq of the 80 DO mice
1	LMP to OBP	<i>Tet1</i>	Adipose (Visceral); 0.3191	-	-
1	LMP to OBP	<i>Tpx2</i>	Testis; 0.2031	-	-
1	LMP to OBP	<i>Cdk1</i>	-	Pituitary; 0.7795	-
1	LMP to OBP	<i>Ttyh3</i>	-	Liver; 0.9350	-
1	LMP to OBP	<i>Olfml3</i>	Artery (Aorta); 0.8048	-	-
1	LMP to OBP	<i>Izumo4</i>	-	Brain (Hypothalamus); 0.9182	-
1	LMP to OBP	<i>Sec24d</i>	Nerve (Tibial); 0.2677	-	-
1	LMP to OBP	<i>Tmem263</i>	Adipose (Subcutaneous); 0.5704	Cultured cells (fibroblasts); 0.9716	-
1	LMP to OBP	<i>Lmf2</i>	-	Adrenal Gland; 0.8181	-
1	LMP to OBP	<i>Tln2</i>	Esophagus (Muscularis); 0.9697	-	-
1	OBP to OB1	<i>Kremen1</i>	Heart (Left Ventricle); 0.8686	-	-

2	OBP to OB2	<i>Kremen1</i>	Heart (Left Ventricle); 0.8686	-	-
2	OBP to OB2	<i>Ebf1</i>	-	Testis; 0.8760	-
2	OBP to OB2	<i>Lrp4</i>	Pancreas; 0.7943	-	-
3	LMP to MALP	<i>Ttyh3</i>	-	Liver; 0.9350	-
3	LMP to MALP	<i>Fgfrl1</i>	Cultured cells (fibroblasts); 0.1611	-	-
3	LMP to MALP	<i>Ebf1</i>	-	Testis; 0.8760	-
3	LMP to MALP	<i>Ppp1rl2b</i>	-	Nerve (Tibial); 0.8807	-
3	LMP to MALP	<i>Rhoj</i>	Cultured cells (fibroblasts); 0.352	Breast; 0.7844	-
3	LMP to MALP	<i>Tln2</i>	Esophagus (Muscularis); 0.9697	-	-
3	MALP to end	<i>Adh1</i>	-	Esophagus (Gastroesophageal Junction); 0.9999	-
3	MALP to end	<i>Fgfrl1</i>	Cultured cells (fibroblasts); 0.1611	-	-
3	MALP to end	<i>Adcy5</i>	-	Esophagus (Gastroesophageal Junction); 0.8456	-
3	MALP to end	<i>Cnn2</i>	-	Spleen; 0.7743	-
3	MALP to end	<i>Mxra8</i>	-	Pituitary; 0.7545	-
3	MALP to end	<i>Timp2</i>	-	Testis; 0.9429	-

279

280 **Network analysis predict *Fgfrl1* and *Tpx2* as novel regulators of BMD:**

281

282 Here we highlight two DDGs that putatively impact human BMD via their roles in LMP

283 differentiation along either an adipogenic (*Fgfrl1*) or osteogenic (*Tpx2*) trajectory, which are

284 genes with potential roles that have been minimally characterized in the context of human BMD.

285 Based on our previous work<sup>7</sup>, *Fgfrl1* (fibroblast growth factor receptor-like 1) was identified as a


286 DDG with significant human BMD GWAS associations that also colocalized with eQTL

287 identified in the cultured fibroblast GTEx tissue (RCP = 0.1611, **Table 1**). The *Fgfrl1* network  
288 was enriched for tradeSeq-identified genes (N = 6 genes,  $P_{adj} = 7.5 \times 10^{-3}$ ) for LMPs along an  
289 adipogenic trajectory (**Figure 5A**). An increase in the expression of all tradeSeq-identified genes  
290 for the *Fgfrl1* network was observed (**Figure 5B, Supplementary File 2d**). Importantly, the  
291 expression pattern for the tradeSeq-identified genes were consistent with the cell type boundaries  
292 established for LMPs differentiating along the adipogenic trajectory toward the MALP cell state  
293 (**Figure 5B**). Furthermore, in the surrounding *Fgfrl1* network, two genes (*Plpp3* and *Cfap100*)  
294 have significant human BMD GWAS associations that also colocalized with sQTL in GTEx  
295 tissues, as reported in our previous study<sup>16</sup>. In the *Fgfrl1* network, many other genes can be  
296 associated with adipocyte function (e.g., *Lpl*, *Plpp3*, *Igfbp4*)<sup>30-32</sup> and the maintenance of cilia  
297 (e.g., *Cfap100*, *St5 (Denn2b)*, *Mark1*)<sup>33-35</sup>.

298 The other network we identified, the *Tpx2* network, was identified for LMPs along an  
299 osteogenic trajectory (**Figure 5C**). *Tpx2* (TPX2, microtubule-associated) is a DDG with  
300 significant human BMD GWAS associations that also colocalized with eQTL identified in the  
301 Testis GTEx tissue (RCP = 0.2031, **Table 1**). The network was enriched for tradeSeq-identified  
302 genes (N = 9 genes,  $P_{adj} = 5.7 \times 10^{-7}$ ) for LMPs differentiating along the osteogenic trajectory  
303 (**Figure 5C**). Furthermore, the expression of the tradeSeq-identified genes for the *Tpx2* network  
304 were consistent with the cell type boundaries established for LMPs differentiating along the  
305 osteogenic trajectory toward the OBP (osteoblast progenitor) cell state (**Figure 5D; Supplementary File 2b**). The expression of these genes increase as LMPs differentiate into  
306 OBPs and subsequently decrease upon reaching an OBP cell state. Additionally, *Tpx2* exhibited  
307 a significant alteration of BMD in both male and female mutant mice (Genotype P-value = 1.03  
308  $\times 10^{-3}$ ) from IMPC (**Figure 5E**). In regards to the constituents of the *Tpx2* network, additional

310 genes have been tested by the IMPC and result in a significant impact on BMD, such as *Ube2c*,  
311 *Top2a*, and *Papss1*. Many other genes in the *Tpx2* network can be associated with cellular  
312 division and proliferation, including four of the genes of the kinesin family (*Kif*) motor protein  
313 genes<sup>36</sup>: *Kif4*, *Kif11*, *Kif15*, *Kif23*.

314



315 **Figure 5. *Fgf11* and *Tpx2* are prioritized DDGs and putative drivers of mesenchymal  
 316 differentiation.**

317

318 **Discussion**

319

320 BMD GWAS has been successful at identifying thousands of SNPs associated with  
321 disease; however, the identification of causal genes and defining their functional role in disease  
322 remains challenging. The integration of “-omics” data, particularly transcriptomics, can assist in  
323 overcoming this challenge. Leveraging transcriptomics data has proven invaluable to informing  
324 GWAS, as demonstrated in studies that use these data to perform eQTL mapping, transcriptome-  
325 wide association studies (TWASs), and co-expression/gene regulatory network reconstruction.  
326 GWAS associations can colocalize with predicted sources of genetic variation that perturb causal  
327 gene function or expression, thus providing a potential mechanism through which associations  
328 impact disease. While bulk RNA-seq data has been the foundation of such analyses, scRNA-seq  
329 data can provide valuable biological context by predicting the cell type in which causal genes are  
330 affected. To inform BMD GWAS, the generation of population-scale transcriptomics data at  
331 single-cell resolution in bone-relevant cell types can assist in the discovery of novel gene targets.  
332 Here, we perform scRNA-seq on 80 DO mice to generate single-cell transcriptomics data of  
333 mesenchymal cell types relevant to bone. Using these data, our goal was to prioritize putative  
334 causal genes and provide biological context in which these genes potentially influence disease, at  
335 cell type-specific resolution. Through our pseudotemporal gene expression and network  
336 analyses, we identified 21 networks governed by predicted differentiation driver genes (DDGs)  
337 that have corresponding human BMD GWAS associations colocalizing with eQTL/sQTL in a  
338 GTEx tissue.

339 We demonstrate that the BMSC-OB model serves as an effective method to enrich for  
340 mesenchymal lineage cells, particularly bone-relevant cells. We characterized cells from 80 mice  
341 and identified both osteogenic and adipogenic cells derived from the mesenchymal lineage, such

342 as two populations of osteoblasts (OB1 and OB2), osteocyte-like cells (Ocy), and MALPs. Our  
343 trajectory inference analysis identified three distinct trajectories in which mesenchymal  
344 progenitor cells give rise to both osteogenic and adipogenic cell types, thus portraying  
345 biologically relevant and known paths of differentiation of mesenchymal progenitor cells.  
346 Pseudotemporal gene expression was analyzed along each trajectory, in a cell type-specific  
347 fashion, to identify genes that were changing the most as a function of pseudotime (tradeSeq-  
348 identified genes). Subsequent *cis*-eQTL analysis indicated that the expression of some tradeSeq-  
349 identified genes were associated with the relative proportion of cell types. While instances such  
350 as these were rare, they illustrate that the potential consequence of genetic variation impacting  
351 the expression of tradeSeq-identified genes may impact differentiation and the abundances of  
352 certain cell types along a trajectory.

353 To inform BMD GWAS, we utilized the scRNA-seq data in a network analysis to  
354 contextualize causal genes (and their associated networks) by predicting the cell types through  
355 which these genes are likely acting. Towards this goal, we generated cell type-specific Bayesian  
356 networks from our BMSC-OB scRNA-seq data. Our approach was similar to our previous  
357 network analyses where bulk RNA-seq data was leveraged to identify genes with strong  
358 evidence of playing central roles in networks<sup>10,11,14</sup>. In contrast, here we utilized scRNA-seq data  
359 to identify DDGs and prioritize networks based on the likelihood that they are involved in the  
360 differentiation of mesenchymal lineage cells (based on network connections enriched for  
361 tradeSeq-identified genes determined from inferred trajectories). Leveraging our previous  
362 work<sup>7,16</sup>, we prioritized DDGs if they were genes with BMD GWAS associations colocalizing  
363 with human eQTL/sQTL in a GTEx tissue. Together, a gene being both a DDG and having BMD  
364 GWAS associations that colocalize with eQTL/sQTL is strong support of causality.

365 We identified 21 DDGs and associated networks, some of which have little to no known  
366 prior connection to bone. We contextualize these causal genes and their networks by not only  
367 providing cell type predictions in which they likely operate, but also providing information  
368 regarding the biological processes they likely affect. For example, the *Tpx2* network was  
369 identified in LMPs differentiating along an osteogenic trajectory. *Tpx2* is a microtubule assembly  
370 factor that interacts with spindle microtubules during cellular division<sup>37</sup>. The expression of *Tpx2*  
371 and its regulation is associated with osteosarcoma, as well as other cancers<sup>38</sup>. In our previous  
372 study, *Tpx2* was identified as a gene that has BMD GWAS associations that colocalize with  
373 eQTL in the Testis GTEx tissue<sup>7</sup>. While GTEx does not maintain bone tissue, eQTL are shared  
374 across many tissues<sup>21</sup>; therefore, non-bone eQTL may exert their effects in cell types associated  
375 with bone, such as LMPs, and evidence of a human eQTL effect indicates that genetic variation  
376 can modulate the expression of *Tpx2*. Additionally, when knocked out by IMPC, *Tpx2* exhibited  
377 a significant increase in whole body BMD in mice, thus providing strong support for *Tpx2*  
378 influencing the regulation of BMD in humans. In the surrounding gene neighborhood of the *Tpx2*  
379 network, other genes can be associated with cellular division as well, such as Topoisomerase 2A  
380 (*Top2a*) and the kinesin family (*Kif*) genes<sup>36,39</sup>. Taken together, these results indicate a potential  
381 role of *Tpx2* as a mediator of BMD and genetic variation altering its expression could affect  
382 microtubule maintenance during the expansion of osteogenic cell populations.

383 Additionally, the *Fgfrl1* network was identified in LMPs differentiating along an  
384 adipogenic trajectory. Fibroblast growth factor receptor-like 1 (*Fgfrl1*) is presumed to function  
385 as a decoy receptor that interacts with FGF ligands necessary for FGF signaling<sup>40,41</sup> and *Fgfrl1*  
386 expression is suggested to play a role in both adipogenic and osteogenic differentiation<sup>42</sup>. Our  
387 previous study also identified *Fgfrl1*, which has BMD GWAS associations that colocalize with

388 eQTL in the cultured fibroblasts GTEx tissue<sup>14</sup>. In the neighborhood of the *Fgfrl1* network, *Lpl*,  
389 *Plpp3*, *Igfbp4* have well-established roles in adipocyte function and metabolism<sup>30–32</sup>; however,  
390 other genes can be associated with cilia, such as *Cfap100*, *St5* (*Denn2b*), *Mark1*<sup>33–35</sup>.  
391 Interestingly, the maintenance and remodeling of cilia is essential to the differentiation of  
392 mesenchymal stem cells and pre-adipocytes (e.g., MALPs) while mature adipocytes lack cilia<sup>43</sup>.  
393 Moreover, the inactivation of FGF signaling is associated with the length of primary cilia<sup>44</sup>.  
394 Thus, genetic variation altering the expression of expression of *Fgfrl1* may affect FGF signaling  
395 to impact the maintenance of cilia and adipogenic differentiation. Additionally, given the  
396 prioritization of MALPs in the CELLECT analysis and the well-established inverse relationship  
397 between marrow adiposity and BMD<sup>45,46</sup>, skewed balance of LMP differentiation toward marrow  
398 adipogenic cell fates may affect BMD. In summary, the *Fgfrl1* network harbors genes involved  
399 in adipogenic function, including cilia maintenance, which may contribute to LMP  
400 differentiation along an adipogenic trajectory. Together, these results indicate a potential role of  
401 *Fgfrl1* as a mediator of BMD via its role in adipogenic differentiation and maintenance of cilia.

402 Analyses performed here are not without limitations to consider. Our *in vitro* culturing  
403 approach and the preparation of single cells for scRNA-seq could be sources of technical  
404 variation in our study. Additionally, a pitfall of scRNA-seq is the sparsity of the resulting data,  
405 which yields an increased frequency of zero values for the expression of some genes in a  
406 proportion of cells, also known as “drop-outs”<sup>47</sup>. While statistical approaches can be employed to  
407 impute missing data, the accuracy of such methods and whether or not the resulting improvement  
408 in transcriptomic signal recovery is enough to warrant such intervention is contentious<sup>48,49</sup>.  
409 However, this issue may be partially offset given the larger scale of the scRNA-seq performed in  
410 this study and the average expression approach performed for network and eQTL analysis.

411 Another limitation of this study is that read alignment of the scRNA-seq data did not account for  
412 DO founder genetic variation in RNA transcripts, which could affect read mapping and gene  
413 expression measurements. An additional limitation is that the BMSC-OB model does not capture  
414 osteoclasts, another cell type associated with bone tissue. Importantly, results from our  
415 CELLECT analysis indicate that BMD heritability was not enriched for genes whose expression  
416 was more specific to osteoclast-like cells; however, these cells likely represent immature  
417 osteoclasts, as mature multinucleated cells would be too large to be captured for sequencing.  
418 Lastly, while our study employed 80 DO mice, the issue of statistical power is still a limitation;  
419 however, we demonstrate that the BMSC-OB model is amenable to high throughput and the  
420 inclusion of hundreds of mice, thus statistical power will be improved in future studies.

421 In summary, we showcase the use of large-scale scRNA-seq data to inform GWAS by  
422 performing a network analysis to contextualize BMD GWAS associations. Through the use of  
423 multiple single-cell analyses, we have expanded upon our understanding of the genetics of BMD.  
424 Our work exemplifies the power of single-cell transcriptomics from large populations of  
425 genetically diverse samples and our network approach for data analysis may guide future studies  
426 to consider systems genetics strategies for the discovery of genetic determinants of disease.

427

428 **Methods**

429

430 **Sample preparation and scRNA-seq**

431

432 All animal procedures were conducted in compliance with the National Institutes of  
433 Health Guide for the Care and Use of Laboratory Animals. The protocol for studies involving  
434 Diversity Outbred mice (Protocol Number 3741) was reviewed and approved by the Institutional  
435 Animal Care and Use Committee (IACUC) at the University of Virginia. We prepared our  
436 samples in the same fashion as performed previously in Al-Barghouthi and colleagues<sup>15</sup>. In brief,  
437 bone marrow was extracted from the femurs of initially 77 DO mice (The Jackson Laboratory,  
438 Strain: 009376) . BMSCs were grown to confluence after 3 days of incubation in 48-well plates  
439 and then underwent *in vitro* osteoblast differentiation for 10 days with osteogenic differentiation  
440 media (alpha MEM, 10% FBS, 1% pen/strep, 1% Glutamax, 50  $\mu$ g/ $\mu$ L ascorbic acid [Sigma, St.  
441 Louis, MO, USA], 10  $\mu$ nM B-glycerophosphate [Sigma], 10  $\mu$ nM dexamethasone [Sigma]).  
442 After differentiation, single cells were liberated from mineralizing cultures via incubations with  
443 60  $\mu$ mM ethylenediaminetetraacetic acid pH 7.4 (EDTA [Thermo Fisher Scientific], made in  
444 DPBS), 8  $\mu$ g/mL collagenase (Gibco) in HBSS/4  $\mu$ mM CaCl<sub>2</sub> (Fisher), and 0.25% trypsin–  
445 EDTA (Gibco). After single-cell isolation, cells from mice were pooled into groups containing  
446 cells from four to five mice total and concentrated to 800 cells/ $\mu$ L in PBS supplemented with  
447 0.1% BSA (bovine serum albumin). Pooled single cells were prepared for sequencing using the  
448 10 $\times$  Chromium Controller (10 $\times$  Genomics, Pleasanton, CA, USA) with the Single Cell 3' v2  
449 reagent kit, according to the manufacturer's protocol. Libraries were sequenced on the  
450 NextSeq500 (Illumina, San Diego, CA, USA).

451

452 **scRNA-seq analysis pipeline**

453

454 The data was subsequently processed using the 10 $\times$  Genomics Cell Ranger toolkit  
455 (version 5.0.0) using the GRCm38 reference genome<sup>50</sup>. Using Seurat<sup>51</sup> (version 4.1.0), a  
456 combined Seurat object containing all cells was generated with the inclusion of features detected  
457 in at least three cells and cells with at least 200 features detected. We used Souporcell<sup>52</sup> (version  
458 2.0.0) to deconvolve the genotypes of all mice and to remove doublet cells. Cells were assigned  
459 to their associated DO mouse by making a pairwise comparison between allele calls made by the  
460 shared variants captured between Souporcell and GigaMUGA genotype arrays generated for all  
461 mice in the cohort, as previous performed in Dillard and colleagues<sup>15</sup>. Cell derived from two  
462 mice (176 and 244) were removed in some analyses due to poor genotyping of their respective  
463 Souporcell clusters, thus yielding a total of 75 DO mice from this study and 5 DO mice from our  
464 previous study<sup>15</sup> for a total of 80 DO mouse biological replicates. We filtered out cells with more  
465 than 6200 reads and less than 400 reads, as well as those cells with more than 10% mitochondrial  
466 reads. Further, cells were removed if they expressed greater than 20% *Rpl* and 15% *Rps* reads,  
467 which equates to cells approximately exceeding the 98 percentile. After filtering, 139,392 cells  
468 remained and the resulting object underwent standard normalization, scaling, and the top 3000  
469 features were modeled from a variance stabilizing transformation (VST) using Seurat. Cell-cycle  
470 markers based on Tirosh and colleagues<sup>53</sup> were regressed out using the “CellCycleScoring” and  
471 scaling functions. For subsequent dimensionality reduction, 15 principal components (PCs) were  
472 summarized. Then, a kNN ( $k=20$ ) graph was created and the Louvain algorithm was used to  
473 cluster cells at a resolution of 0.5. Annotation of cell type clusters was performed manually  
474 based on differential gene expression analysis using the Seurat “FindAllMarkers” function  
475 (**Supplementary File 1a**).

476 For subsequent WGCNA and eQTL mapping, transcriptomic profiles for each cell type  
477 cluster were generated for each sample using a mean expression approach, as performed  
478 similarly by others<sup>54,55</sup>. For each sample contributing at least 5 cells to a given cluster,  
479 unnormalized unique molecular identifier (UMI) counts of gene expression for all cells in the  
480 cluster for the sample were averaged and then rounded to the nearest hundredth decimal place. A  
481 total of 80, 80, 77, 67, 50, 76, 80 mice contributed enough cells to the MPC, LMP, OBP, OB1,  
482 OB2, Ocy, and MALP cell type clusters, respectively. Genes with non-zero expression values in  
483 fewer than 15 samples were removed. A total of 11971, 15162, 14857, 13674, 13825, 14136, and  
484 14534 genes remained for the MPC, LMP, OBP, OB1, OB2, Ocy, and MALP clusters,  
485 respectively. Samples were normalized by computing CPMs (counts per million) without log  
486 transformation for each gene using edgeR<sup>56</sup> (version 4.0.7), then transformed via VST using  
487 DESeq2<sup>57</sup> (version 1.42.0), and quantile normalized using preprocessCore (version 1.60.2).

488  
489 **Trajectory and tradeSeq Analysis**  
490

491 Trajectory inference analysis was performed using Slingshot<sup>58</sup> (version 1.8.0) on the  
492 mesenchymal lineage cell clusters (seven total) of the BMSC-OB scRNA-seq data. The starting  
493 cluster was set as the MPC cluster upon the removal of a small outlier population of cells.  
494 Trajectories were inferred using 15 PCs. TradeSeq<sup>27</sup> (version 1.4.0) was used to analyze gene  
495 expression along the trajectories by fitting a negative binomial generalized additive model (NB-  
496 GAM) to each gene using the “fitGAM” function with nknots = 10, which was determined by  
497 using the “evaluateK” function. Prior to performing the tradeSeq analysis, the scRNA-seq data  
498 was downsampled to reduce the size of the dataset to approximately 10,000 cells (sampled at  
499 random across all seven clusters).

500 All cell type boundaries were established to encompass on average 78% of cells of a cell  
501 cluster (**Supplementary File 2a**). To identify genes significantly changing between boundaries  
502 in a trajectory-specific fashion, we first performed tradeSeq to compare gene expression within  
503 each trajectory (two osteogenic, one adipogenic) to highlight genes with a significant difference  
504 in expression between boundaries using the “startVsEndTest” function (**Supplementary File 2a-**  
505 **d**). Next, we performed a global test with tradeSeq to compare gene expression between  
506 trajectories in order to highlight genes exhibiting a significant difference in expression using the  
507 “startVsEndTest” function (**Supplementary File 2a, Supplementary File 2e**). All tests were  
508 performed with the  $\log_2$  fold change threshold ( $l2fc$ ) = 0.5. For all global and trajectory-specific  
509 tests, the P-values associated with each gene were adjusted to control the false discovery rate  
510 using the “p.adjust” function from the stats (version 4.2.1) R package and genes were filtered to  
511 include those with a  $P_{adj} < 0.05$ .

512

513 **CELLECT Analysis**

514

515 CELLECT<sup>20</sup> (CELL-type Expression-specific integration for Complex Traits) (version  
516 1.1.0) was used to identify likely etiologic cell types underlying complex traits of both the  
517 BMSC-OBs scRNA-seq data (**Figure 1E, Supplementary File 1f**). CELLECT P-values were  
518 adjusted using the Bonferroni correction. CELLECT quantifies the association between the  
519 GWAS signal and cell type expression specificity using the S-LDSC genetic prioritization  
520 model<sup>59</sup>. Summary statistics from the UK Biobank eBMD and Fracture GWAS (Data Release  
521 2018) and cell type annotations from each scRNA-seq data set were used as input. Cell type  
522 expression specificities were estimated using CELLEX<sup>20</sup> (CELL-type EXpression-specificity)  
523 (version 1.2.1) (**Supplementary File 3g**).

524

## 525 WGCNA

526

527 Cell type-specific mean expression matrices (as obtained above) were used as input to  
528 generate signed co-expression network modules (**Supplementary File 1g-h**). IterativeWGCNA<sup>22</sup>  
529 (version 1.1.6) was used from a Singularity container built from a Docker hub image<sup>60</sup>. A soft  
530 threshold (power) of 14, which exceeded a  $R^2$  threshold of 0.85 for all cell type clusters, was  
531 selected for module construction (**Figure 2-figure supplement 1**). Modules were generated  
532 using iterativeWGCNA with default parameters for the “blockwiseModules” function, a  
533 minimum module size of 20 genes, minCoreKME = 0.7, and minKMEtoStay = 0.5.

534

## 535 Bayesian network learning

536

537 Bayesian networks were learned from each of the cell type-specific modules of co-  
538 expressed genes with the bnlearn (version 4.8.3). Gene expression matrices containing the genes  
539 for each module were used as input to the “mmhc” function which employs the Max-Min Hill  
540 Climbing algorithm (MMHC) algorithm<sup>61</sup> to learn the underlying structure of the Bayesian  
541 network. From the generated networks, igraph (version 1.6.0) was used to resolve 3-step  
542 neighborhoods<sup>62</sup>. Nodes (genes) that were unconnected to a neighborhood or connected to only  
543 one neighbor were removed. Neighborhoods were filtered to include those with a size greater  
544 than 1 standard deviation from the mean across all neighborhoods generated for the network.

545

546 DDGs (differentiation driver genes) are genes that yield large 3-step neighborhoods that  
547 are enriched ( $P_{adj} < 0.05$ ) with tradeSeq-identified genes for a given cell type boundary. We  
548 calculated whether each neighborhood contained more tradeSeq-identified genes (for the  
549 neighborhoods’ associated cell type boundary) than would be expected by chance using the  
hypergeometric distribution (“phyper” function) from the stats (version 4.2.1) R package. The

550 arguments were as follows:  $q$ : (number of neighbors in a neighborhood that are also tradeSeq-  
551 identified genes for a given cell type boundary) – 1;  $m$ : total number of tradeSeq-identified genes  
552 for a given cell type boundary;  $n$ : (total number of identified neighborhoods) –  $m$ ;  $k$ :  
553 neighborhood size (total number of neighbors); lower.tail = false. P-values were adjusted to  
554 control the false discovery rate using the “p.adjust” function from the stats (version 4.2.1) R  
555 package. These pruning steps resulted in a total of 408 DDGs and associated networks for all cell  
556 types (**Supplementary File 2h-k**).

557 **DO eQTL mapping**

558  
559 Prior to performing the eQTL analysis, DNA was extracted from the tails of the 80 DO  
560 mice, using the PureLink Genomic DNA mini kit (Invitrogen) and genotyped using the  
561 GigaMUGA array by Neogen Genomics (GeneSeek; Lincoln, NE). Processing and quality  
562 control of genotype data, including calculation of genotype/allele probabilities, was performed  
563 as previously described in Al-Barghouthi and colleagues<sup>14</sup>. Cell type-specific mean expression  
564 matrices (as obtained above) for mesenchymal lineage clusters were used as input for the eQTL  
565 mapping, which was performed using a linear mixed model (LMM) via the “scan1” function  
566 from the qtl2<sup>63</sup> (version 0.30) R package with allowances for the following covariates: sex, age at  
567 sacrifice (in days), weight, length, and DO mouse generation. To identify significant eQTL, we  
568 calculated a LOD (logarithm of the odds) threshold; for each cell type cluster, we chose 50 genes  
569 at random and then permuted them 1000 times using the “scan1perm” function from qtl2. We  
570 established the LOD threshold of 9.68 and 9.49 for the autosomal chromosomes and X  
571 chromosome, respectively, by taking the average of the median LOD across each cell type. A  
572 total of 563 eQTL exceeded the LOD thresholds and were no more than 1 Mbp from the  
573 transcription start site of the associated eGene (**Supplementary File 2f**).

574

575 **Cell type proportion analysis**

576

577 To account for technical sources of variation often retained in scRNA-seq, cell type  
578 proportions were transformed using the arcsin (asin) square root transformation from the  
579 speckle<sup>64</sup> R package (version 0.0.3). Tests of statistical significance were performed using the  
580 propeller t-test and ANOVA functions with default parameters. Sex of the mice and the batch  
581 each mouse was associated with for sequencing were modeled as covariates. Transformed values  
582 were used as input for computing tests of statistical differences of cell type proportions between  
583 mice, as well as correlation to phenotypic traits (**Supplementary File 1c-e**).

584

585 **Data Availability Statement**

586  
587 The data that support the findings of this study are openly available in NCBI Gene  
588 Expression Omnibus database with accession codes GSE152806 and GSE269583. Processed  
589 scRNA-seq data available on Zenodo at <https://zenodo.org/records/15299631>.

590  
591 **Code Availability Statement**

592  
593 Code for analysis is available on GitHub at [https://github.com/Farber-Lab/DO80\\_project](https://github.com/Farber-Lab/DO80_project).

594  
595  
596 **Acknowledgements**  
597  
598 Research reported in this publication was supported in part by the National Institute of  
599 Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under award  
600 numbers R01AR68345, R01AR082880, and R01AR077992 to CRF.

601  
602 **Disclosures**  
603  
604 The authors declare no competing interests.

605  
606

607  
608

## Figure Legends

609  
610

### Figure 1. Analysis of single cell RNA-seq (scRNA-seq) data for BMSC-OBs derived from 80 Diversity Outbred (DO)

611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623

(A) Uniform Manifold Approximation and Projection (UMAP) of 139,392 single cells (BMSC-OBs). Cell numbers and corresponding percentages for the fifteen (15) annotated cell clusters are listed in parenthesis to the right of the annotated cluster name. (B) Dot plot<sup>65</sup> portraying representative and highly expressed genes for all annotated cell clusters. Dot color indicates the scaled gene expression while the size of the dot corresponds to the percentage of cells of a given cluster that express a given gene. (C) The raw proportional abundances of seven (7) mesenchymal cell clusters and one (1) cluster (Hem) representing the remain cells (i.e., mainly hematopoietic immune cells) across all 80 DO mice. (D) UMAP plots for mesenchymal lineage cell clusters for DO mouse 50 and DO mouse 233. (E) CELLECT (CELL-type Expression-specific integration for Complex Traits) cell type prioritization results displaying the Bonferroni adjusted P-values for the cell clusters. The OB1, Ocy, and MALP cell clusters (red) were significantly enriched ( $P_{adj} < 0.05$ , red dashed line) for BMD heritability ( $P_{adj} = 0.018, 0.010, 0.006$ , respectively).

624

625

### Figure 2. Overview of the network analysis pipeline

626  
627  
628  
629  
630  
631  
632  
633  
634  
635

Step 1: For all seven (7) of the mesenchymal lineage cell clusters (MPC, LMP, OBP, OB1, OB2, Ocy, MALP), cell type-specific co-expression modules were generated using iterative Weighted Gene Co-expression Network Analysis (iterativeWGCNA). Step 2: Bayesian networks were learned to generate directed networks and model causal interactions between co-expressed genes. Step 3: Differentiation Driver Genes (DDGs) were identified by extracting subnetworks (i.e., large 3-step neighborhood) for each gene in each cell type-specific Bayesian network and highlighting those subnetworks that were enriched ( $P_{adj} < 0.05$ ) for trajectory-specific tradeSeq genes for the cell type boundary. Step 4: DDGs (and associated networks) were prioritized if the DDG was identified previously as an expression/splicing quantitative trait loci (eQTL/sQTL) that colocalized with BMD GWAS associations. Created with Biorender.com.

636

637  
638

### Figure 3. Pseudotime Trajectory Inference analysis and establishment of cell type boundaries for tradeSeq analysis

639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649

(A) Three (3) trajectories (two adipogenic, one adipogenic) were inferred from the mesenchymal cell clusters of the BMSC-OB scRNA-seq data using Slingshot. All trajectories originate from the MPC and end in either osteogenic (Ocy, OB2) or adipogenic (MALP) cell fates. (B) For each of the trajectories, cell type boundaries were generated using pseudotime values along the trajectories, which encompass the majority of cells of a cell type mapping to their respective trajectory. (C) Normalized gene expression of select genes associated with each cluster are represented in feature plots (*top*) and each gene plotted as a function of pseudotime (*bottom*) for all pseudotime trajectories (color corresponds to cell type annotation observed throughout). Vertical lines (red) represent the cell type (pseudotime) boundaries established for each cell type (label). The cell type boundary for OB1 and OB2 are represented as one red line/label for visualization purposes.

650  
651  
652

653 **Figure 4. TradeSeq-identified genes associated with BMSC-OB differentiation exhibit**  
654 **eQTL effects.**

655 (A) *Pkm* was identified as a significant global tradeSeq-identified gene ( $P_{adj} = 8.35 \times 10^{-8}$ ) for  
656 LMP cells along an osteogenic trajectory (LMP\_to\_OBP) (left). *S100a1* was identified as a  
657 significant global tradeSeq-identified gene ( $P_{adj} = 0.023$ ) for OBP cells along osteogenic  
658 trajectory 1 (OBP\_to\_OB1) (right). (B) Plots indicating the cell type-specific expression  
659 quantitative trait loci (eQTL) signal for both *Pkm* and *S100a1*. A negative eQTL effect on *Pkm*  
660 expression was observed in LMPs for Diversity Outbred (DO) mice with a PWK haplotype  
661 background at the *Pkm* locus (left). A positive eQTL effect on the expression of *S100a1* was  
662 observed in OBPs for DO mice with a 129 haplotype background at the *S100a1* locus, while a  
663 negative effect was observed for NZO mice (right). (C) The expression of *Pkm* and *S100a1*  
664 based on DO mouse (expression values transformed via variance stabilizing transformation  
665 (VST), as described in Methods). Genotype abbreviations correspond to DO haplotype  
666 background (legend) at the respective gene locus. Mice with at least one PWK allele (genotype  
667 abbreviation G) tend to have decreased expression of *Pkm* (left). Mice with at least one 129 allele  
668 (genotype abbreviation C) tend to have increased expression of *S100a1*, while NZO mice  
669 (genotype abbreviation E) have decreased expression (right). (D) PWK mice had a significant  
670 reduction in mature osteoblasts (OB1) and osteocyte-like cells (Ocy) proportions relative to other  
671 mice ( $P = 0.030$  and  $P = 0.026$ , respectively; t-test), while LMP proportions were unaffected.  
672 Asterisks represent any of the other haplotype backgrounds. 129 mice showed a significant  
673 decrease in LMP proportion and increase in OB1 proportion ( $P = 0.008$  and  $P = 0.016$ ,  
674 respectively; t-test), but OBP proportions were unaffected. No significant effects on cell type  
675 proportions were observed in NZO mice (Figure 4-figure supplement 1).

676

677 **Figure 5. *Fgfrl1* and *Tpx2* are prioritized DDGs and putative drivers of mesenchymal**  
678 **differentiation.**

679 (A) *Fgfrl1* was identified as a Differentiation Driver Gene (DDG) of a network for LMPs  
680 differentiating along an adipogenic trajectory. The network is enriched ( $P_{adj} = 7.5 \times 10^{-3}$ ) for  
681 trajectory-specific tradeSeq-identified genes for the LMP\_to\_MALP cell type boundary (*Hnmt*,  
682 *St5*, *Igfbp4*, *Cyp1b1*, *Pdzrn4*, *Mark1*). *Fgfrl1* was previously identified as a gene that has BMD  
683 GWAS associations that colocalize with an eQTL in the cultured fibroblast GTEx tissue. (B) An  
684 increase in the expression of tradeSeq-identified genes coincides with the LMP\_to\_MALP cell  
685 type boundary in which they were identified as significant. (C) *Tpx2* was identified as a DDG of  
686 a network for LMPs differentiating along an osteogenic trajectory. The network is enriched ( $P_{adj}$   
687 =  $5.7 \times 10^{-7}$ ) for tradeSeq-identified genes for the LMP\_to\_OBP cell type boundary (*Tpx2*,  
688 *Top2a*, *Kif4*, *Iqgap3*, *Prc1*, *Kif11*, *Ect2*, *Sgo2a*, *Ube2c*). *Tpx2* is both a tradeSeq gene and  
689 previously identified as a gene that has BMD GWAS associations that colocalize with an eQTL  
690 in the Testis GTEx tissue. (D) An increase in the expression of tradeSeq-identified genes  
691 coincides with the LMP\_to\_OBP cell type boundary in which they were identified as significant.  
692 (E) Box plot displaying whole-body bone mineral density (BMD) measurements (excluding  
693 skull) from the International Mouse Knockout Consortium (IMPC) for *Tpx2* mutant mice, which  
694 exhibited a significant increase in BMD (Genotype P-value =  $1.03 \times 10^{-3}$ ) in both male and  
695 female mice (N = 8 (M) and 8 (F) mutants; N = 2574 (M) and 2633 (F) controls)

696

697  
698

## Supplementary Figure Legends

699  
700  
701  
702  
703  
704  
705

**Figure 1-figure supplement 1:** Plots displaying the distribution of the total number of cells from each mouse (N = 80). A) Density plot portraying the distribution of the total number of cells from each mouse after processing of the scRNA-seq data. B) Boxplot displaying the distribution of the total number of cells for each mouse (Min: 723, 1st Qu: 1316, Median: 1690, Mean: 1742, 3rd Qu: 2118, Max: 3652). C) Quantile-quantile plot (Q-Q plot) with 95% confidence interval. Shapiro-Wilk normality test: p-value = 0.1061; W = 0.97425.

706  
707  
708  
709  
710

**Figure 2-figure supplement 1:** Scale Free Topology and Mean Connectivity graphs for the cell type-specific iterativeWGCNA analysis. A soft thresholding power of 14 was selected for the generation of all co-expression modules for all clusters, which was the point at which R<sup>2</sup> exceeded a threshold of 0.85

711  
712  
713  
714  
715  
716

**Figure 4-figure supplement 1:** Tests of significance for cell type proportions for NZO mice. Mice with at least one NZO allele at the *S100a1* locus (N = 14) had no significant difference in cell type proportions (P > 0.05; t-test) as compared mice with other DO haplotype background at this locus. Asterisks represent any of the other haplotype backgrounds.

717  
718

## Supplementary File Legends

719  
720  
721  
722

**Supplementary File 1a:** Differentially Expressed Genes (DEGs) for all clusters of the BMSC-OB scRNA-seq cell clusters. DEGs were calculated on all clusters of the BMSC-OB scRNA-seq data using the FindAllMarkers function from the Seurat R package.

723  
724  
725  
726

**Supplementary File 1b:** Differentially Expressed Genes (DEGs) between the OB1 and OB2 clusters of the scRNA-seq data. DEGs were calculated using the FindMarkers function from the Seurat R package. Positive values for average log2 fold change (avg\_log2FC) indicate that a gene is more highly expressed in OB1.

727  
728  
729  
730  
731  
732

**Supplementary File 1c:** BMSC-OB cell type proportion analysis for the 80 DO mice. The raw proportions (top) and asin-transformed proportions (bottom) of each of the BMSC-OB cell types were calculated from the total number of cells contributed by each mouse using the Propeller R package. All non-mesenchymal lineage cell types (i.e., Hematopoietic lineage cells) are aggregated as a group (Hem) for each mouse.

733  
734  
735  
736  
737

**Supplementary File 1d:** Correlation of cell proportions to bone trait metrics captured from the 80 DO mice. Raw (top) and transformed (bottom) cell type proportions were correlated using Pearson and Spearman to bone trait metrics (55 total) captured on all mice from the 80 DO mice.

738  
739

**Supplementary File 1e:** Bone trait abbreviations and units of measurement.

740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750

**Supplementary File 1f:** CELLECT cell type prioritization table. Beta is regression effect size estimate for given annotation. Beta SE is the standard error for the regression coefficient. The p value is the one-sided test ( $\beta > 0$ ) association between bone mineral density (BMD) genome wide association study (GWAS) signal heritability and each annotated cell type. P values were adjusted using the Bonferroni correction method. MALP = marrow adipogenic lineage precursors; Ocy = osteocyte-like cell; OB1 = osteoblast population 1; MPC = mesenchymal progenitor cell; LMP = late mesenchymal progenitor; OBP = osteoblast progenitor; OB2 = osteoblast population 2; EC = endothelial cell; MF1 = macrophage population 1; MO = Monocyte; BC = B-cell; GC = granulocyte; OC = osteoclast-like cell; TC = T-cell; MF2 = macrophage population 2.

751  
752  
753  
754  
755

**Supplementary File 1g:** Summary of results from the iterativeWGCNA analysis. A total of 535 co-expression modules were generated using the mesenchymal lineage cell clusters (7 total) of the BMSC-OB scRNA-seq data, yielding an average of 76 modules per cell cluster. A total of 8810 Bayesian networks were generated from the co-expression modules.

756  
757  
758

**Supplementary File 1h:** Genes within each module generated from the iterativeWGCNA analysis.

759  
760  
761  
762

**Supplementary File 2a:** Summary of tradeSeq-identified genes. For each cell type (pseudotime) boundary associated with a specific trajectory (9 total), a global and trajectory- specific test was performed using the startVsEndTest function from the tradeSeq R Package. The number of genes identified for each test and for each boundary are displayed, as well as the number of tradeSeq-

763 identified genes that were also identified as eGenes from the eQTL mapping of the 80 DO mice  
764 (73 total).

765  
766 **Supplementary File 2b:** TradeSeq-identified genes from the trajectory-specific analysis for  
767 Osteogenic Trajectory 1. All significant trajectory-specific tradeSeq-identified genes  
768 ( $P_{adj} \leq 0.05$ ) across all cell type boundaries (5 total; MPC, LMP, OBP, OB1, Ocy) associated  
769 with Osteogenic Trajectory 1. Associated eQTL information is also displaced for the gene if it  
770 was an eGene identified in the cell type from the cell type-specific eQTL analysis (if “NA” is  
771 present, the gene was not identified as an eGene).

772  
773 **Supplementary File 2c:** TradeSeq-identified genes from the trajectory-specific analysis for  
774 Osteogenic Trajectory 2. All significant trajectory-specific tradeSeq-identified genes  
775 ( $P_{adj} \leq 0.05$ ) across all cell type boundaries (2 total; OBP, OB2) associated with Osteogenic  
776 Trajectory 2. Associated eQTL information is also displaced for the gene if it was an eGene  
777 identified in the cell type from the cell type-specific eQTL analysis (if “NA” is present, the gene  
778 was not identified as an eGene).

779  
780 **Supplementary File 2d:** TradeSeq-identified genes from the trajectory-specific analysis for the  
781 Adipogenic Trajectory. All significant trajectory-specific tradeSeq-identified genes  
782 ( $P_{adj} \leq 0.05$ ) across all cell type boundaries (2 total; LMP, MALP) associated with the  
783 Adipogenic Trajectory. Associated eQTL information is also displaced for the gene if it was an  
784 eGene identified in the cell type from the cell type-specific eQTL analysis (if “NA” is present,  
785 the gene was not identified as an eGene).

786  
787 **Supplementary File 2e:** TradeSeq-identified genes from the global analysis. All significant  
788 global tradeSeq-identified genes ( $P_{adj} \leq 0.05$ ) across all cell type (pseudotime) boundaries (9  
789 total). Associated eQTL information is also displaced for the gene if it was an eGene identified  
790 in the cell type from the cell type-specific eQTL analysis (if “NA” is present, the gene was not  
791 identified as an eGene).

792  
793 **Supplementary File 2f:** Results from the cell type-specific eQTL analysis on the mesenchymal  
794 lineage cell types identified in the scRNA-seq data from the 80 DO mice. All significant eQTL  
795 (LOD > 9.68 for autosomal chromosomes; LOD > 9.49 for X chromosome) and eGenes for the  
796 mesenchymal cell clusters (563 total). Chr = chromosome of eQTL, Pos = eQTL peak position,  
797 LOD = logarithm of the odds score, ci (low/hi) = LOD support intervals, Start = start position of  
798 gene (GRCm38), End = end position of gene (GRCm38), dist\_start = distance of eQTL to start.

799  
800 **Supplementary File 2g:** Results from tests of significance for cell type proportions. Tests of  
801 significance on the transformed cell type proportions were performed using the Propeller R  
802 package and nominal p-values are reported. Sample batch (pool containing cells from mice in  
803 preparation for scRNA-seq) and sex were modeled as covariates. For the Pkm example, a T-test  
804 was performed for all mice with at least one PWK haplotype background (PWK/\*; asterisk  
805 meaning any DO haplotype) at a Pkm locus ( $n = 15$ ) against all remaining mice ( $n = 65$ ). For the  
806 S100a1 example, a one-way ANOVA was performed on four groups: mice with at least one  
807 129/\* haplotype background ( $n = 26$ ) or NZO/\* ( $n = 10$ ), heterozygous for both (129/NOZ,  $n =$   
808 4), or any other DO haplotype background at the locus ( $n = 40$ ). Additionally, T-tests were

809 performed on the 129/\* and NZO/\* haplotype background individually against all other mice  
810 aggregated as a group.  
811

812 **Supplementary File 2h:** Summary of Differentiation Driver Gene (DDG) network analysis. The  
813 number of DDGs and associated networks that were enriched ( $P_{adj} \leq 0.05$ ) with more genes in  
814 the trajectory-specific tradeSeq genes for each cell type boundary (408 total). The number of  
815 DDGs that had a corresponding human homolog with a human BMD GWAS association (that  
816 colocalizes with expression and/or splicing quantitative trait loci (eQTL/sQTL) from the  
817 Genotype-Tissue Expression (GTEx) Project) are also displayed (26 total, 21 distinct). Three of  
818 the DDGs were also tested by the IMPC and had a significant BMD phenotype when knocked  
819 out.  
820

821 **Supplementary File 2i:** All significant DDG network analysis for Osteogenic trajectory 1 (178  
822 total). The enrichment of each DDG Bayesian network for tradeSeq-identified genes (identified  
823 for each cell type boundary along Osteogenic Linage 1) are displayed as nominal and adjusted P-  
824 values, as well as the co-expression module in which the DDG was identified. The data can be  
825 filtered to highlight DDGs that are: a tradeSeq-identified gene for the cell boundary, a gene that  
826 was identified by Al-Barghouthi et al. (2022) as having eQTL that also colocalizes with BMD  
827 GWAS associations, a gene that was identified by Abood et al. (2023) as having sQTL that also  
828 colocalizes with BMD GWAS associations, a gene that was tested by the IMPC and had a  
829 significant effect on BMD when knocked out, or gene that was identified here as an eGene in the  
830 cell type-specific eQTL analysis using the 80 DO scRNA-seq data. Other columns of the data  
831 contain information at the network level: Number\_neighbors = number of nodes (genes) in  
832 Bayesian network, Number\_tradeSeq\_gene\_neighbors = number of genes that were also  
833 tradeSeq-identified genes for the cell type boundary, All network neighbors = all genes in  
834 network, Neighbors\_eQTL\_Al\_Barghouthi = all genes in the network that were identified from  
835 Al-Barghouthi et al. (2022), Neighbors\_sQTL\_Abood = all genes in the network that were  
836 identified from Abood et al. (2023), Neighbors\_IMPC\_BMD\_gene = all genes in the network  
837 that were tested by the IMPC and had a significant effect on BMD when knocked out,  
838 Neighbors\_DO\_eGene = all genes in the network that was identified here as an eGene in the cell  
839 type-specific eQTL analysis using the 80 DO scRNA-seq data,  
840 Neighbors\_tradeSeq\_gene\_for\_boundary = all genes that were also tradeSeq-identified genes for  
841 the cell type boundary.  
842

843 **Supplementary File 2j:** All significant DDG network analysis for Osteogenic trajectory 2 (55  
844 total). The enrichment of each DDG Bayesian network for tradeSeq-identified genes (identified  
845 for cell type boundary along Osteogenic Linage 2) are displayed as nominal and adjusted P-  
846 values, as well as the co-expression module in which the DDG was identified. The data can be  
847 filtered to highlight DDGs that are: a tradeSeq-identified gene for the cell boundary, a gene that  
848 was identified by Al-Barghouthi et al. (2022) as having eQTL that also colocalizes with BMD  
849 GWAS associations, a gene that was identified by Abood et al. (2023) as having sQTL that also  
850 colocalizes with BMD GWAS associations, a gene that was tested by the IMPC and had a  
851 significant effect on BMD when knocked out, or gene that was identified here as an eGene in the  
852 cell type-specific eQTL analysis using the 80 DO scRNA-seq data. Other columns of the data  
853 contain information at the network level: Number\_neighbors = number of nodes (genes) in  
854 Bayesian network, Number\_tradeSeq\_gene\_neighbors = number of genes that were also

855 tradeSeq-identified genes for the cell type boundary, All network neighbors = all genes in  
856 network, Neighbors\_eQTL\_Al\_Barghouthi = all genes in the network that were identified from  
857 Al-Barghouthi et al. (2022), Neighbors\_sQTL\_Abood = all genes in the network that were  
858 identified from Abood et al. (2023), Neighbors\_IMPC\_BMD\_gene = all genes in the network  
859 that were tested by the IMPC and had a significant effect on BMD when knocked out,  
860 Neighbors\_DO\_eGene = all genes in the network that was identified here as an eGene in the cell  
861 type-specific eQTL analysis using the 80 DO scRNA-seq data,  
862 Neighbors\_tradeSeq\_gene\_for\_boundary = all genes that were also tradeSeq-identified genes for  
863 the cell type boundary  
864

865 **Supplementary File 2k:** All significant DDG network analysis for the Adipogenic trajectory  
866 (175 total). The enrichment of each DDG Bayesian network for tradeSeq-identified genes  
867 (identified for cell type boundary along the Adipogenic trajectory) are displayed as nominal and  
868 adjusted P-values, as well as the co-expression module in which the DDG was identified. The  
869 data can be filtered to highlight DDGs that are: a tradeSeq-identified gene for the cell boundary,  
870 a gene that was identified by Al-Barghouthi et al. (2022) as having eQTL that also colocalizes  
871 with BMD GWAS associations, a gene that was identified by Abood et al. (2023) as having  
872 sQTL that also colocalizes with BMD GWAS associations, a gene that was tested by the IMPC  
873 and had a significant effect on BMD when knocked out, or gene that was identified here as an  
874 eGene in the cell type-specific eQTL analysis using the 80 DO scRNA-seq data. Other columns  
875 of the data contain information at the network level: Number\_neighbors = number of nodes  
876 (genes) in Bayesian network, Number\_tradeSeq\_gene\_neighbors = number of genes that were  
877 also tradeSeq-identified genes for the cell type boundary, All network neighbors = all genes in  
878 network, Neighbors\_eQTL\_Al\_Barghouthi = all genes in the network that were identified from  
879 Al-Barghouthi et al. (2022), Neighbors\_sQTL\_Abood = all genes in the network that were  
880 identified from Abood et al. (2023), Neighbors\_IMPC\_BMD\_gene = all genes in the network  
881 that were tested by the IMPC and had a significant effect on BMD when knocked out,  
882 Neighbors\_DO\_eGene = all genes in the network that was identified here as an eGene in the cell  
883 type-specific eQTL analysis using the 80 DO scRNA-seq data,  
884 Neighbors\_tradeSeq\_gene\_for\_boundary = all genes that were also tradeSeq-identified genes for  
885 the cell type boundary  
886

887 **Supplementary File 3a:** PANTHER Gene Ontology (GO) Enrichment analysis for DDGs  
888 identified for the LMP to OBP cell type boundary (Osteogenic trajectory 1).  
889

890 **Supplementary File 3b:** PANTHER Gene Ontology (GO) Enrichment analysis for DDGs  
891 identified for the OBP to OB1 cell type boundary (Osteogenic trajectory 1).  
892

893 **Supplementary File 3c:** PANTHER Gene Ontology (GO) Enrichment analysis for DDGs  
894 identified for the OBP to OB2 cell type boundary (Osteogenic trajectory 2).  
895

896 **Supplementary File 3d:** PANTHER Gene Ontology (GO) Enrichment analysis for DDGs  
897 identified for the LMP to MALP cell type boundary (Adipogenic trajectory).  
898

899 **Supplementary File 3e:** PANTHER Gene Ontology (GO) Enrichment analysis for DDGs  
900 identified for the MALP to the end (of the trajectory) cell type boundary (Adipogenic trajectory).

901  
902 **Supplementary File 3f:** Prioritized DDG network analysis for the Adipogenic trajectory (26  
903 total, 21 distinct). The enrichment of each prioritized DDG Bayesian network for  
904 tradeSeq-identified genes (identified for the cell type boundary along the associated trajectory)  
905 are displayed as nominal and adjusted P-values, as well as the co-expression module in which the  
906 DDG was identified. The data can be filtered to highlight DDGs that are: a tradeSeq-identified  
907 gene for the cell boundary, a gene that was identified by Al-Barghouthi et al. (2022) as having  
908 eQTL that also colocalizes with BMD GWAS associations, a gene that was identified by Abood  
909 et al. (2023) as having sQTL that also colocalizes with BMD GWAS associations, a gene that  
910 was tested by the IMPC and had a significant effect on BMD when knocked out, or gene that  
911 was identified here as an eGene in the cell type-specific eQTL analysis using the 80 DO  
912 scRNAseq data. Other columns of the data contain information at the network level:  
913 Number\_neighbors = number of nodes (genes) in Bayesian network,  
914 Number\_tradeSeq\_gene\_neighbors = number of genes that were also tradeSeq-identified genes  
915 for the cell type boundary, All network neighbors = all genes in network,  
916 Neighbors\_eQTL\_Al\_Barghouthi = all genes in the network that were identified from Al-  
917 Barghouthi et al. (2022), Neighbors\_sQTL\_Abood = all genes in the network that were identified  
918 from Abood et al. (2023), Neighbors\_IMPC\_BMD\_gene = all genes in the network that were  
919 tested by the IMPC and had a significant effect on BMD when knocked out,  
920 Neighbors\_DO\_eGene = all genes in the network that was identified here as an eGene in the cell  
921 type-specific eQTL analysis using the 80 DO scRNA-seq data,  
922 Neighbors\_tradeSeq\_gene\_for\_boundary = all genes that were also tradeSeq-identified genes for  
923 the cell type boundary  
924  
925 **Supplementary File 3g:** Expression Specificity scores ( $ES\mu$ ) scores for each gene for each cell  
926 cluster of the BMSC-OB scRNA-seq data for the 80 DO mice.  $ES\mu$  scores are generated during  
927 the CELLEX portion of the CELLECT analysis pipeline.  $ES\mu$  values range from 0 to 1 and are a  
928 gene's marginal likelihood of being specifically expressed in a given cell type, where 1 is the  
929 most specific and 0 is not specific.  
930  
931

932  
933

## References

934 1. Lin, J. T. & Lane, J. M. Osteoporosis: a review. *Clin. Orthop. Relat. Res.* 126–134 (2004).

935 2. Peacock, M., Turner, C. H., Econs, M. J. & Foroud, T. Genetics of osteoporosis. *Endocr. Rev.* **23**, 303–326 (2002).

936 3. Johnell, O. *et al.* Predictive value of BMD for hip and other fractures. *J. Bone Miner. Res.* **20**, 1185–1194 (2005).

937 4. Morris, J. A. *et al.* An atlas of genetic influences on osteoporosis in humans and mice. *Nat. Genet.* **51**, 258–266 (2019).

938 5. Cookson, W., Liang, L., Abecasis, G., Moffatt, M. & Lathrop, M. Mapping complex disease  
939 traits with global gene expression. *Nat. Rev. Genet.* **10**, 184–194 (2009).

940 6. Wen, X., Pique-Regi, R. & Luca, F. Integrating molecular QTL data into genome-wide  
941 genetic association analysis: Probabilistic assessment of enrichment and colocalization.  
942 *PLoS Genet.* **13**, e1006646 (2017).

943 7. Al-Barghouthi, B. M. *et al.* Transcriptome-wide association study and eQTL colocalization  
944 identify potentially causal genes responsible for human bone mineral density GWAS  
945 associations. *Elife* **11**, (2022).

946 8. Li, B. & Ritchie, M. D. From GWAS to Gene: Transcriptome-Wide Association Studies  
947 and Other Methods to Functionally Understand GWAS Discoveries. *Front. Genet.* **12**,  
948 713230 (2021).

949 9. Akiyama, M. Multi-omics study for interpretation of genome-wide association study. *J.*  
950 *Hum. Genet.* **66**, 3–10 (2020).

951 10. Calabrese, G. M. *et al.* Integrating GWAS and Co-expression Network Data Identifies Bone  
952 Mineral Density Genes SPTBN1 and MARK3 and an Osteoblast Functional Module. *Cell Syst* **4**, 46–59.e4 (2017).

953 11. Sabik, O. L., Calabrese, G. M., Taleghani, E., Ackert-Bicknell, C. L. & Farber, C. R.  
954 Identification of a Core Module for Bone Mineral Density through the Integration of a Co-  
955 expression Network and GWAS Data. *Cell Rep.* **32**, 108145 (2020).

956 12. GTEx Consortium. The Genotype-Tissue Expression (GTEx) project. *Nat. Genet.* **45**, 580–  
957 585 (2013).

958 13. GTEx Consortium. The GTEx Consortium atlas of genetic regulatory effects across human  
959 tissues. *Science* **369**, 1318–1330 (2020).

960 14. Al-Barghouthi, B. M. *et al.* Systems genetics in diversity outbred mice inform BMD GWAS  
961 and identify determinants of bone strength. *Nat. Commun.* **12**, 3408 (2021).

962 15. Dillard, L. J. *et al.* Single-Cell Transcriptomics of Bone Marrow Stromal Cells in Diversity  
963 Outbred Mice: A Model for Population-Level scRNA-Seq Studies. *J. Bone Miner. Res.* **38**,  
964 1350–1363 (2023).

965 16. Abood, A. *et al.* Long-read proteogenomics to connect disease-associated sQTLs to the  
966 protein isoform effectors of disease. *bioRxiv* 2023.03.17.531557 (2023)  
967 doi:10.1101/2023.03.17.531557.

968 17. Bogue, M. A., Churchill, G. A. & Chesler, E. J. Collaborative Cross and Diversity Outbred  
969 data resources in the Mouse Phenome Database. *Mamm. Genome* **26**, 511–520 (2015).

970 18. Churchill, G. A., Gatti, D. M., Munger, S. C. & Svenson, K. L. The Diversity Outbred  
971 mouse population. *Mamm. Genome* **23**, 713–718 (2012).

972 19. Zhong, L. *et al.* Single cell transcriptomics identifies a unique adipose lineage cell  
973 population that regulates bone marrow environment. *Elife* **9**, (2020).

974

975

976

977

978 20. Timshel, P. N., Thompson, J. J. & Pers, T. H. Genetic mapping of etiologic brain cell types  
979 for obesity. *Elife* **9**, (2020).

980 21. GTEx Consortium *et al.* Genetic effects on gene expression across human tissues. *Nature*  
981 **550**, 204–213 (2017).

982 22. Greenfest-Allen, E., Cartailler, J.-P., Magnuson, M. A. & Stoeckert, C. J. iterativeWGCNA:  
983 iterative refinement to improve module detection from WGCNA co-expression networks.  
984 *bioRxiv* 234062 (2017) doi:10.1101/234062.

985 23. Chan, C. K. F. *et al.* Identification of the Human Skeletal Stem Cell. *Cell* **175**, 43-56.e21  
986 (2018).

987 24. Mizuhashi, K. *et al.* Resting zone of the growth plate houses a unique class of skeletal stem  
988 cells. *Nature* **563**, 254–258 (2018).

989 25. Debnath, S. *et al.* Discovery of a periosteal stem cell mediating intramembranous bone  
990 formation. *Nature* **562**, 133–139 (2018).

991 26. Matsushita, Y. *et al.* A Wnt-mediated transformation of the bone marrow stromal cell  
992 identity orchestrates skeletal regeneration. *Nat. Commun.* **11**, 332 (2020).

993 27. Van den Berge, K. *et al.* Trajectory-based differential expression analysis for single-cell  
994 sequencing data. *Nat. Commun.* **11**, 1201 (2020).

995 28. Thomas, P. D. *et al.* PANTHER: Making genome-scale phylogenetics accessible to all.  
996 *Protein Sci.* **31**, 8–22 (2022).

997 29. Groza, T. *et al.* The International Mouse Phenotyping Consortium: comprehensive  
998 knockout phenotyping underpinning the study of human disease. *Nucleic Acids Res.* **51**,  
999 D1038–D1045 (2023).

1000 30. Enerbäck, S., Ohlsson, B. G., Samuelsson, L. & Bjursell, G. Characterization of the human  
1001 lipoprotein lipase (LPL) promoter: evidence of two cis-regulatory regions, LP-alpha and  
1002 LP-beta, of importance for the differentiation-linked induction of the LPL gene during  
1003 adipogenesis. *Mol. Cell. Biol.* **12**, 4622–4633 (1992).

1004 31. Federico, L. *et al.* Lipid phosphate phosphatase 3 regulates adipocyte sphingolipid  
1005 synthesis, but not developmental adipogenesis or diet-induced obesity in mice. *PLoS One*  
1006 **13**, e0198063 (2018).

1007 32. Maridas, D. E., DeMambro, V. E., Le, P. T., Mohan, S. & Rosen, C. J. IGFBP4 Is Required  
1008 for Adipogenesis and Influences the Distribution of Adipose Depots. *Endocrinology* **158**,  
1009 3488–3500 (2017).

1010 33. Sigg, M. A. *et al.* Evolutionary Proteomics Uncovers Ancient Associations of Cilia with  
1011 Signaling Pathways. *Dev. Cell* **43**, 744-762.e11 (2017).

1012 34. Kumar, R. *et al.* A cell-based GEF assay reveals new substrates for DENN domains and a  
1013 role for DENND2B in primary ciliogenesis. *Sci Adv* **8**, eabk3088 (2022).

1014 35. Fumoto, K. *et al.* Mark1 regulates distal airspace expansion through type I pneumocyte  
1015 flattening in lung development. *J. Cell Sci.* **132**, (2019).

1016 36. Miki, H., Setou, M., Kaneshiro, K. & Hirokawa, N. All kinesin superfamily protein, KIF,  
1017 genes in mouse and human. *Proc. Natl. Acad. Sci. U. S. A.* **98**, 7004–7011 (2001).

1018 37. Zhang, R., Roostalu, J., Surrey, T. & Nogales, E. Structural insight into TPX2-stimulated  
1019 microtubule assembly. *Elife* **6**, (2017).

1020 38. Zhu, D., Xu, X., Zhang, M. & Wang, T. TPX2 regulated by miR-29c-3p induces cell  
1021 proliferation in osteosarcoma via the AKT signaling pathway. *Oncol. Lett.* **23**, 143 (2022).

1022 39. Uusküla-Reimand, L. & Wilson, M. D. Untangling the roles of TOP2A and TOP2B in  
1023 transcription and cancer. *Sci Adv* **8**, eadd4920 (2022).

1024 40. Trueb, B. Biology of FGFR1, the fifth fibroblast growth factor receptor. *Cell. Mol. Life*  
1025 *Sci.* **68**, 951–964 (2011).

1026 41. Steinberg, F. *et al.* The FGFR1 receptor is shed from cell membranes, binds fibroblast  
1027 growth factors (FGFs), and antagonizes FGF signaling in Xenopus embryos. *J. Biol. Chem.*  
1028 **285**, 2193–2202 (2010).

1029 42. Kähkönen, T. E. *et al.* Role of fibroblast growth factor receptors (FGFR) and FGFR like-1  
1030 (FGFR1) in mesenchymal stromal cell differentiation to osteoblasts and adipocytes. *Mol.*  
1031 *Cell. Endocrinol.* **461**, 194–204 (2018).

1032 43. Hilgendorf, K. I. Primary Cilia Are Critical Regulators of White Adipose Tissue Expansion.  
1033 *Front. Physiol.* **12**, 769367 (2021).

1034 44. Neugebauer, J. M., Amack, J. D., Peterson, A. G., Bisgrove, B. W. & Yost, H. J. FGF  
1035 signalling during embryo development regulates cilia length in diverse epithelia. *Nature*  
1036 **458**, 651–654 (2009).

1037 45. Fazeli, P. K. *et al.* Marrow fat and bone--new perspectives. *J. Clin. Endocrinol. Metab.* **98**,  
1038 935–945 (2013).

1039 46. Veldhuis-Vlug, A. G. & Rosen, C. J. Clinical implications of bone marrow adiposity. *J.*  
1040 *Intern. Med.* **283**, 121–139 (2018).

1041 47. Haque, A., Engel, J., Teichmann, S. A. & Lönnberg, T. A practical guide to single-cell  
1042 RNA-sequencing for biomedical research and clinical applications. *Genome Med.* **9**, 75  
1043 (2017).

1044 48. Cheng, Y., Ma, X., Yuan, L., Sun, Z. & Wang, P. Evaluating imputation methods for single-  
1045 cell RNA-seq data. *BMC Bioinformatics* **24**, 302 (2023).

1046 49. Yu, X., Abbas-Aghababazadeh, F., Chen, Y. A. & Fridley, B. L. Statistical and  
1047 Bioinformatics Analysis of Data from Bulk and Single-Cell RNA Sequencing Experiments.  
1048 *Methods Mol. Biol.* **2194**, 143–175 (2021).

1049 50. Church, D. M. *et al.* Lineage-specific biology revealed by a finished genome assembly of  
1050 the mouse. *PLoS Biol.* **7**, e1000112 (2009).

1051 51. Hao, Y. *et al.* Integrated analysis of multimodal single-cell data. *Cell* **184**, 3573–3587.e29  
1052 (2021).

1053 52. Heaton, H. *et al.* Souporcell: robust clustering of single-cell RNA-seq data by genotype  
1054 without reference genotypes. *Nat. Methods* **17**, 615–620 (2020).

1055 53. Tirosh, I. *et al.* Dissecting the multicellular ecosystem of metastatic melanoma by single-  
1056 cell RNA-seq. *Science* **352**, 189–196 (2016).

1057 54. Neavin, D. *et al.* Single cell eQTL analysis identifies cell type-specific genetic control of  
1058 gene expression in fibroblasts and reprogrammed induced pluripotent stem cells. *Genome*  
1059 *Biol.* **22**, 76 (2021).

1060 55. van der Wijst, M. G. P. *et al.* Single-cell RNA sequencing identifies celltype-specific cis-  
1061 eQTLs and co-expression QTLs. *Nat. Genet.* **50**, 493–497 (2018).

1062 56. Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for  
1063 differential expression analysis of digital gene expression data. *Bioinformatics* **26**, 139–140  
1064 (2010).

1065 57. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion  
1066 for RNA-seq data with DESeq2. *Genome Biol.* **15**, 550 (2014).

1067 58. Street, K. *et al.* Slingshot: cell lineage and pseudotime inference for single-cell  
1068 transcriptomics. *BMC Genomics* **19**, 477 (2018).

1069 59. Finucane, H. K. *et al.* Partitioning heritability by functional annotation using genome-wide  
1070 association summary statistics. *Nat. Genet.* **47**, 1228–1235 (2015).

1071 60. Cartailler, J. P. *Iterativewgcna*. (2022).

1072 61. Tsamardinos, I., Brown, L. E. & Aliferis, C. F. The max-min hill-climbing Bayesian  
1073 network structure learning algorithm. *Mach. Learn.* **65**, 31–78 (2006).

1074 62. Porter, M. D. & Smith, R. Network neighborhood analysis. in *2010 IEEE International  
1075 Conference on Intelligence and Security Informatics* (IEEE, 2010).  
1076 doi:10.1109/isi.2010.5484781.

1077 63. Broman, K. W. *et al.* R/qtl2: Software for Mapping Quantitative Trait Loci with High-  
1078 Dimensional Data and Multiparent Populations. *Genetics* **211**, 495–502 (2019).

1079 64. Phipson, B. *et al.* propeller: testing for differences in cell type proportions in single cell  
1080 data. *Bioinformatics* **38**, 4720–4726 (2022).

1081 65. Marsh, S., Salmon, M. & Hoffman, P. *Custom Visualizations & Functions for Streamlined  
1082 Analyses of Single Cell Sequencing*. (2023). doi:10.5281/zenodo.7534950.